ReviewDiscovery medicine2011
Inflammasome activation in obesity-related inflammatory diseases and autoimmunity.
Review in Discovery medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The Role of NLRP3 Inflammasome in Obesity and PCOS-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- NLRP3 Inflammasome and Polycystic Ovary Syndrome (PCOS): A Novel Profile in Adipose Tissue.International journal of molecular sciences · 2026Article
- Brown adipose tissue: a potential therapeutic target for preventing cardiovascular disease in metabolic disorders.Diabetology & metabolic syndrome · 2025Article
- Unleashing the potential of exercise: conquering cardiovascular disease by targeting inflammasome activation.European journal of medical research · 2025Review
- Association between High Normal TSH Levels and Obesity in Women with Anti-Thyroid Autoantibodies (ATAs).Journal of clinical medicine · 2022Article
- Metabolic transformation of fat in obesity determines the inflammation resolving capacity of splenocardiac and cardiorenal networks in heart failure.American journal of physiology. Heart and circulatory physiology · 2022Article
- Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity.Frontiers in immunology · 2022Review
- Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications.Frontiers in endocrinology · 2022Review
- Emerging Roles of Inflammasomes in Cardiovascular Diseases.Frontiers in immunology · 2022Review
- Bariatric surgery-induced weight loss reduces B cell activating cytokines and IgG immunoglobulins related to autoimmunity.Surgical endoscopy · 2021Observational
- Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer's Disease.International journal of molecular sciences · 2021Review
- NLRP3 inflammasome in cancer and metabolic diseases.Nature immunology · 2021Review
- Hyperuricemia, Elevated Body Mass Index, Female Sex, and Albuminuria Increase the Probability of Elevated High-Sensitivity C-Reactive Protein: Results From the National Health and Nutrition Examination Survey 2015-2018.Frontiers in public health · 2021Article
- Review
- Integrative analyses of biomarkers and pathways for adipose tissue after bariatric surgery.Adipocyte · 2020Article
- Novel Function of α-Cubebenoate Derived fromMolecules (Basel, Switzerland) · 2020Article
- Role of tri-ponderal mass index in cardio-metabolic risk assessment in children and adolescents: compared with body mass index.International journal of obesity (2005) · 2020Article
- Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus.World journal of diabetes · 2020Review
- Integrative Analysis of the Genes Induced by the Intestine Microbiota of Infant Born to Term and Breastfed.Bioinformatics and biology insights · 2020Article
- Saturated Fatty Acids in Obesity-Associated Inflammation.Journal of inflammation research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The inflammasome is a highly regulated protein complex that triggers caspase-1 activation and subsequent secretion of IL-1β and IL-18. Recognition of microbial components and danger signals by NOD-like receptor (NLR) family members in the cytosol promotes inflammasome activation and downstream inflammatory cytokine production. Pathogen recognition by NLRs and downstream release of inflammasome-derived cytokines are important in host defense against numerous infections. Recent studies have also identified a unique role for inflammasome regulation in the induction and pathogenesis of multiple autoimmune and inflammatory disorders. We now know that obesity-related factors and endogenous markers of cellular stress can lead to unchecked activation of the inflammasome and provoke inflammation and subsequent destruction of vital organs. This review will highlight recent findings that link inflammasome signaling to the progression of autoinflammatory and autoimmune diseases. We will focus on the contribution of inflammasome activation to the pathogenesis of autoinflammatory and autoimmune diseases that are of major significance to human health including type 2 diabetes, atherosclerosis, multiple sclerosis, and type 1 diabetes.
Indexed as
Identifiers
21794210PMC4266394W2289195527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.